Eli Lilly Cuts 340B Discounts for 50 Hospitals Over Claims Data Refusal

Lilly notified non-compliant hospitals in June 2026 following its January policy requiring duplicate-discount verification. Over 2,300 hospitals submitted data and retained discounts, while up to 1,000 initially resisted and a core group of 50 larger systems continued to refuse. The company cited program integrity concerns, yet hospitals argue the demands exceed statutory authority under the 340B statute.

This action extends a multi-year pattern of manufacturers restricting 340B access to pressure transparency. Similar moves by other firms have prompted lawsuits and congressional hearings. Observational data from HRSA audits show duplicate discounts occur in 5-10 percent of claims, but Lilly's selective enforcement targets high-volume systems and may shift costs to uninsured patients without addressing root pricing opacity.

Hospitals now face revenue shortfalls estimated at 2-4 percent of outpatient drug spend. Trade groups seek legislative overrides, while CMS has signaled possible guidance updates. The next 90 days will test whether additional manufacturers replicate the tactic or courts intervene before widespread patient access changes materialize.